Le Galès Catherine
Centre de recherche médecine, sciences, santé, santé mentale, société (CERMES3), Inserm U 988, CNRS UMR 8211, École des hautes études en sciences sociales, université Paris Descartes, 7, rue Guy Môquet, 94801 Villejuif Cedex, France.
Med Sci (Paris). 2018 Jan;34(1):83-86. doi: 10.1051/medsci/20183401018. Epub 2018 Jan 31.
According to the Organization for Economic Co-operation and Development (OECD), drug expenditures account for about 20 % of all health expenditures in high-income countries. The increase of these drug expenditures which has been observed in all these countries over a long period is due to the combination of aging populations, changes in medical practices and the dynamics of the pharmaceutical market, in particular the hospital market. France is no exception. Its consumption of drugs (which accounted for 17.5 % of health expenditures in 2014), historically among the highest in volume, has grown slower in the last decade than in other OECD countries. However, the particularly rapid and wide adoption of pharmaceutical innovations, which has always characterized France, has had in recent years a very significant effect on the soaring drug expenditures covered by the social protection system (plus 1.1 billion in 2014, a year marked by the introduction of new therapies against hepatitis C). This significant effect should continue with the introduction of new and very expensive therapies, particularly in oncology.
根据经济合作与发展组织（经合组织）的数据，在高收入国家，药品支出约占所有医疗支出的20%。长期以来，所有这些国家的药品支出都在增加，这是由于人口老龄化、医疗实践的变化以及制药市场（尤其是医院市场）的动态变化共同作用的结果。法国也不例外。其药品消费（2014年占医疗支出的17.5%），从历史上看数量一直处于高位，在过去十年中的增长速度低于其他经合组织国家。然而，法国一直以来对药物创新的特别迅速和广泛采用，近年来对社会保障系统所涵盖的药品支出飙升产生了非常重大的影响（2014年增加了11亿，这一年以引入抗丙型肝炎新疗法为标志）。随着新的、非常昂贵的疗法的引入，这种重大影响将继续存在，尤其是在肿瘤学领域。
